SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

LIVTENCITY

TAK·TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already marketed (FDA-approved November 2021)
Why 3/10
No upcoming PDUFA date, AdComm, or pivotal topline readout is scheduled for LIVTENCITY in the next 12 months; the drug is already approved and commercialized, and Takeda is a large diversified pharma, so this drug alone will not drive a binary stock move.
Actionable Insight NEUTRAL

Watch for updates in Takeda's patent litigation against Qilu Pharmaceutical (ANDA filed 2026) which could affect LIVTENCITY's generic timeline; also monitor quarterly sales growth rate and any label expansion progress for first-line CMV treatment. The drug's next material catalyst would be a successful front-line indication trial, but none is currently on a near-term regulatory calendar.

Price Chart

Loading chart...

Executive Summary

LIVTENCITY (maribavir) is Takeda's first-in-class oral antiviral for post-transplant cytomegalovirus (CMV) infection that is refractory to standard therapies. FDA-approved in November 2021 and now available in 30+ countries including Japan, the drug holds a unique niche as the only approved treatment for resistant/refractory post-transplant CMV. Sales reached JPY 14.1 billion (~$93M) in Q1 FY2026, growing 21% year-over-year, implying a ~$370M annual run rate. However, it represents only about 1.25% of Takeda's total revenue, and the AURORA Phase 3 trial for a larger first-line indication failed in 2022. NCE exclusivity expired in November 2025, and Takeda is now in patent litigation with generic challenger Qilu Pharmaceutical. With no upcoming PDUFA or pivotal readout, the drug is a steady commercial performer but not a near-term binary catalyst for Takeda shares.

How It Works

LIVTENCITY is an antiviral pill that treats cytomegalovirus (CMV), a common herpes-family virus that can cause serious illness in organ or stem cell transplant patients. It works by blocking a specific CMV enzyme (pUL97 kinase) that the virus needs to replicate, stopping the infection from spreading. It is taken orally twice a day.

Trial Status

Approved based on the pivotal Phase 3 SOLSTICE trial. A Phase 3 study for front-line CMV treatment (AURORA) missed its primary endpoint. A Phase 3 study in Chinese adults with CMV infections completed in July 2026. Multiple real-world evidence and post-marketing studies are ongoing.

The Two-Sided Case

▲ Bull Case5
First and only FDA-approved drug specifically for post-transplant CMV infection/disease that is refractory to conventional antivirals, addressing a significant unmet medical need (source: fda.gov)
Q1 FY2026 sales of JPY 14.1 billion (roughly $93M) grew 20.8% at constant currency, driven by strong US performance; annualized run rate around JPY 56B ($370M) (source: investing.com)
Approved in 30+ countries including Japan (June 2024), providing geographic expansion upside (source: takeda.com/newsroom)
Key patents extend into the 2040s (latest listed through October 2043 per FDA Orange Book), providing long market exclusivity if upheld against generic challengers (source: cliffbio.com)
Takeda is actively defending its patent portfolio, having filed multiple infringement lawsuits against Qilu Pharmaceutical for generic maribavir in 2026 (source: bloomberglaw.com)
▼ Bear Case5
NCE (new chemical entity) exclusivity expired November 2025, opening the door for generic ANDA filers; Qilu Pharmaceutical filed for generic maribavir in 2026, triggering patent litigation from Takeda (source: bloomberglaw.com)
The Phase 3 AURORA trial evaluating maribavir as a first-line treatment for CMV in hematopoietic stem cell transplant recipients missed its primary endpoint in 2022, limiting label expansion prospects (source: takeda.com/newsroom)
LIVTENCITY represents only ~1.25% of Takeda's ¥4.5 trillion ($28B) annual revenue, so swings in this drug's sales have minimal stock impact for the parent company
Competition from Merck's Prevymis (letermovir) in CMV prophylaxis and Roche's Valcyte (valganciclovir) in treatment limits LIVTENCITY's addressable market to the refractory/resistant segment
Maribavir resistance emerged in 26% of treated patients in one Phase 3 SOLSTICE analysis, a potential long-term usage headwind (source: academic.oup.com/jid)

Upcoming Catalysts

  • Patent litigation outcome against Qilu Pharmaceutical (ANDA challenge, ongoing) could affect generic entry timeline
  • Quarterly sales growth trajectory in Takeda earnings reports
  • Any future data from label-expansion trials for first-line CMV treatment
  • Potential additional geographic approvals or launches

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report

Sources · 11

Hover a chip for the title
1 takeda.com2 fda.gov3 accessdata.fda.gov4 investing.com5 news.bloomberglaw.com6 takeda.com7 takeda.com8 cliffbio.com9 en.wikipedia.org10 takeda.com11 academic.oup.com